Entresto (sacubitril/valsartan) is protected by multiple patent families owned by Novartis. The protections cover things like the fixed-dose combination itself, the individual components, methods of use (e.g., treating heart failure), formulations, and manufacturing/process aspects. In short: yes, there are patent protections, but the exact expiry dates vary by country and by patent family.
Key points:
- There are several patent families around composition-of-matter, fixed-dose combinations, and therapeutic use.
- Patents in different jurisdictions expire at different times, and can be affected by extensions (e.g., pediatric extensions, regulatory exclusivity like data protection or SPCs in the EU).
- Once the core patents expire in a given market, generic versions may enter, subject to any remaining patent protections.
If you tell me the country/region you’re interested in (e.g., US, EU, UK, Japan, etc.), I can outline the likely expiry window and point you to the specific patent families or numbers to check. Note that for legal certainty you may want to consult a patent attorney or check official patent databases (USPTO Patent Center, EPO Espacenet, Google Patents, etc.).